Mesenchymal stromal cells do not increase the risk of viral reactivation nor the severity of viral events in recipients of allogeneic stem cell transplantation

Stem Cells International

Volumn , Issue , 2012, Pages

  Lucchini, Giovanna ^a   Dander, Erica ^b   Pavan, Fabio ^a   Di Ceglie, Irene ^b   Balduzzi, Adriana ^a   Perseghin, Paolo ^a   Gaipa, Giuseppe ^a   Algarotti, Alessandra ^c   Introna, Martino ^c   Rambaldi, Alessandro ^c   Rovelli, Attilio ^a   Biondi, Andrea ^a,b   Biagi, Ettore ^a,b   D'Amico, Giovanna ^b  

^a SAN GERARDO HOSPITAL   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c OSPEDALI RIUNITI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON;

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNE RESPONSE; INFECTION RISK; MESENCHYMAL STEM CELL TRANSPLANTATION; PATIENT MONITORING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK ASSESSMENT; VIRUS REACTIVATION;

EID: 84862296213     PISSN: None     EISSN: 16879678     Source Type: Journal    
DOI: 10.1155/2012/690236     Document Type: Article

References (20)

1. Salem H. K., Thiemermann C. Mesenchymal stromal cells: current understanding and clinical status Stem Cells 2010 28 585 596
2. Le Blanc K., Rasmusson I., Sundberg B., Gtherstrm C., Hassan M., Uzunel M., Ringdén O., Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells Lancet 2004 363 9419 1439 1441 (Pubitemid 38586721)
3. Krampera M., Glennie S., Dyson J., Scott D., Laylor R., Simpson E., Dazzi F., Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide Blood 2003 101 9 3722 3729 (Pubitemid 36857965)
4. Aggarwal S., Pittenger M. F., Human mesenchymal stem cells modulate allogeneic immune cell responses Blood 2005 105 4 1815 1822 (Pubitemid 40223708)
5. Sotiropoulou P. A., Perez S. A., Gritzapis A. D., Baxevanis C. N., Papamichail M., Interactions between human mesenchymal stem cells and natural killer cells Stem Cells 2006 24 1 74 85
6. Nauta A. J., Fibbe W. E., Immunomodulatory properties of mesenchymal stromal cells Blood 2007 110 10 3499 3506 (Pubitemid 350159613)
7. Dazzi F., Horwood N. J., Potential of mesenchymal stem cell therapy Current Opinion in Oncology 2007 19 6 650 655 (Pubitemid 47508875)
8. Ramasamy R., Tong C. K., Seow H. F., Vidyadaran S., Dazzi F., The immunosuppressive effects of human bone marrow-derived mesenchymal stem cells target T cell proliferation but not its effector function Cellular Immunology 2008 251 2 131 136
9. Karlsson H., Samarasinghe S., Ball L. M., Sundberg B., Lankester A. C., Dazzi F., Uzunel M., Rao K., Veys P., Le Blanc K., Ringdén O., Amrolia P. J., Mesenchymal stem cells exert differential effects on alloantigen and virus-specific T-cell responses Blood 2008 112 3 532 541
10. Le Blanc K., Tammik L., Sundberg B., Haynesworth S. E., Ringdén O., Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex Scandinavian Journal of Immunology 2003 57 1 11 20 (Pubitemid 38019084)
11. Ljungman P., Molecular monitoring of viral infections after hematopoietic stem cell transplantation International Journal of Hematology 2010 91 4 596 601
12. Capelli C., Domenghini M., Borleri G., Bellavita P., Poma R., Carobbio A., Mic C., Rambaldi A., Golay J., Introna M., Human platelet lysate allows expansion and clinical grade production of mesenchymal stromal cells from small samples of bone marrow aspirates or marrow filter washouts Bone Marrow Transplantation 2007 40 8 785 791 (Pubitemid 47521539)
13. Dander E., Pira G. L., Biagi E., Perseghin P., Renoldi G., Gaipa G., Introna M., Marin V., Manca F., Biondi A., D'Amico G., Characterization of migratory activity and cytokine profile of helper and cytotoxic CMV-specific T-cell lines expanded by a selective peptide library Experimental Hematology 2008 36 4 473 485
14. Le Blanc K., Frassoni F., Ball L., Locatelli F., Roelofs H., Lewis I., Lanino E., Sundberg B., Bernardo M. E., Remberger M., Dini G., Egeler R. M., Bacigalupo A., Fibbe W., Ringdén O., Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study The Lancet 2008 371 9624 1579 1586 (Pubitemid 351626841)
15. von Bonin M., Stlzel F., Goedecke A., Richter K., Wuschek N., Hlig K., Platzbecker U., Illmer T., Schaich M., Schetelig J., Kiani A., Ordemann R., Ehninger G., Schmitz M., Bornhuser M., Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium Bone Marrow Transplantation 2009 43 3 245 251
16. Dander E., Lucchini G., Introna M., Rovelli A., Balduzzi A., Bonanomi S., Salvad A., Capelli C., Belotti D., Gaipa G., Perseghin P., Vinci P., Lanino E., Chiusolo P., Orofino M. G., Marktel S., Golay J., Rambaldi A., Biondi A., D'Amico G., Biagi E., Mesenchymal stromal cells for the treatment of graft versus-host disease: understanding the in vivo biological effect through patient immune monitoring Leukemia. In press
17. von Bahr L., Sundberg B., Lnnies L., Sander B., Karbach H., Hgglund H., Ljungman P., Gustafsson P., Karlsson H., Le Blanc K., Ringdén O., Long-term complications, immunological effects, and role of passage for outcome in mesenchymal stromal-cell therapy Biology of Blood and Marrow Transplantation 2012 18 557 564
18. Meisel R., Brockers S., Heseler K., Degistirici O., Blle H., Woite C., Stuhlsatz S., Schwippert W., Jger M., Sorg R., Henschler R., Seissler J., Dilloo D., Dubener W., Human but not murine multipotent mesenchymal stromal cells exhibit broad-spectrum antimicrobial effector function mediated by indoleamine 2,3-dioxygenase Leukemia 2011 25 4 648 654
19. Martin P. J., Uberti J. P., Soiffer R. J., Prochymal improves response rate in patients with steroid-refractory acute graft versus host disease (SR-GvHD) involving the liver and gut: results of a randomized, placebo controlled, multicenter phase III trial in GvHD. Oral presentation at EBMT, Wien, Austria, Abstract n.41, 2010
20. Rao K., Rao A., Karlsson H., Jagani M., Veys P., Amrolia P. J., Improved survival and preserved antiviral responses after combination therapy with daclizumab and infliximab in steroid-refractory graft-versus-host disease Journal of Pediatric Hematology/Oncology 2009 31 6 456 461